Viewing Study NCT04761393


Ignite Creation Date: 2025-12-25 @ 1:11 AM
Ignite Modification Date: 2026-01-01 @ 6:36 PM
Study NCT ID: NCT04761393
Status: RECRUITING
Last Update Posted: 2024-11-20
First Post: 2021-02-11
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Characterizing Matrix Metalloproteinase-12 (MMP12) in Sputum
Sponsor: McMaster University
Organization:

Study Overview

Official Title: Characterizing Mmp12 In Sputum And Its Relationship To Emphysema And Inflammatory Endotypes
Status: RECRUITING
Status Verified Date: 2024-11
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The hypothesis is that in patients with emphysema, a high MMP12 sputum and/or blood level correlates with airspace enlargement and with increased sputum Th2 immune biomarkers.
Detailed Description: Since MMP-12 apparently has a preponderant role in the genesis of emphysema and probably in airspace enlargement, its inhibition may result in an interesting targeting point in view to find specific therapies in obstructive diseases. There is abundant evidence in animal models that shows how MMP-12 blockade inhibits the development of emphysema and airway remodeling. Unfortunately, the results have not been conclusive in human models.

In the last years, pulmonary imaging biomarkers that measure airspace enlargement have been developed. In particular, the apparent diffusion coefficient (ADC), quantified by inhaled hyperpolarized gas MRI, reflects alveolar airspace size. ADC provides information consistent with histopathological findings that may be used to estimate lung disease progression and treatment response.

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: